Abstract: The present disclosure provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present disclosure further discloses methods of making and using the FIX fusion proteins.

Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.

Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.

Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.

Abstract: This invention relates to methods of treating sickle cell disease with VLA-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with VLA-4 antagonists.

Abstract: A hydroelectric installation comprises an electric generator and associated hydro-turbine. The hydro-turbine comprises a runner rotatably mounted within a casing or passageway in which water flows between an upper elevation source in fluid communication with an inlet port and a lower elevation discharge region or outlet port. The turbine also includes a water closure component or head cover. The generator is laterally supported by a guide bearing attached to a turbine component thereby eliminating the use of generator guide bearing brackets, bridges and the like, and reducing the complexity of the concrete structures surrounding the unit.

Abstract: The present invention relates to the use of analogs of thrombomodulin ("TM") that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to inhibit the direct procoagulant activities of thrombin, such as, for example, thrombin-mediated conversion of fibrinogen to fibrin. These analogs are useful in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed. Included are methods for increasing the circulating half life of the proteins.

Abstract: Novel soluble oxidation resistant thrombomodulin analogs are produced for various therapeutic and other uses, such as in thrombotic and vascular disease therapies. These analogs exhibit the characteristic therapeutic properties of native thrombomodulin, yet they are soluble and are not inactivated after they have been exposed to oxidants. Some of the analogs disclosed are multifunctional fusion proteins having both antithrombotic activity and some additional bioactivity.

Abstract: Methods for producing ascorbic acid using recombinant means comprising the transfer of genetic material by conjugation, a host cell lacking, entirely or to such an extent as not to be commercially useful, one or more enzymes in the metabolic path converting glucose to 2 keto-L-gulonic acid.

Abstract: A process for the preparation of 2-keto-L-gulonic acid (2-KLG) from 2,5-diketo-D-gluconic acid (2,5-DKG) using a DNA sequence encoding 2,5-DKG reductase. The 2-KLG is a precursor for the synthesis of ascorbic acid (Vitamin C).

Abstract: 2-keto-L-gluonic acid (2-KLG) is prepared from 2,5-diketo-D-gluconic acid (2,5-DKG) using a microorganism containing the enzyme 2,5-DKG reductase produced by an expression plasmid encoding a gene for the enzyme. The product, 2-KLG is a precursor for the synthesis of ascorbic acid (vitamin C).

Abstract: Recombinant plasmids containing the gene encoding 2,5-diketogluconic acid reductase are prepared and used to transform microorganisms. 2,5,DKG reductase is expressed by the microorganisms.

Abstract: The invention is directed to treating soy based foods with an effective amount of starfish trypsin 1 (DIT.sub.1) to inactivate soybean trypsin inhibitor (STI). Also contemplated are the oral administration of starfish trypsin 1 to overcome soybean trypsin inhibitor and pharmaceutical compositions containing starfish trypsin 1.